{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-24-000074","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.561453+00:00","generated_at":"2026-06-01T14:09:16.263532+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exelixis settles CABOMETYX patent litigation; Cipla generic launch from Jan 1, 2031","bullets":["Settlement with Cipla resolves two Hatch-Waxman patent suits over CABOMETYX (cabozantinib).","Cipla receives license to market generic CABOMETYX in US starting January 1, 2031, if FDA approved.","All ongoing Delaware district court litigation will be dismissed pending FTC review.","Agreement confidential and subject to review by FTC and DOJ."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-24-000074","json":"https://secwatch.observer/filing/0000939767-24-000074.json","markdown":"https://secwatch.observer/filing/0000939767-24-000074.md","text":"https://secwatch.observer/filing/0000939767-24-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000074/0000939767-24-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000074/exel-20240520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T14:09:16.263532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}